We entered into a collaboration agreement with Kyinno Bio to co-develop a novel GPRC5D/BCMA/CD3 T-cell engager, MBS314.

We have established a strategic partnership with Pfizer (NYSE: PFE) to accelerate the overseas clinical trial for MBS314.

We have established a product commercialization partnership with Kawin (688687.SH) This collaboration enables us to leverage the product to enhance our own market promotion and sales network more effectively.